SCHEMBL8623985

SCHEMBL8623985

COC(=O)c1cc(-c2ccccc2)cnc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 4/20 0.59
KDM4E B2RXH2 3/20 0.48
SGK1 O00141 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
PIK3CD O00329 1/20 0.46
PIK3CA P42336 1/20 0.46
PIK3CB P42338 1/20 0.46
PIK3CG P48736 1/20 0.46
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
NR4A2 P43354 2/20 0.45
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
NEK1 Q96PY6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11379519 0.87 AXL (0.60) AXLKDM4EPIK3CDPIK3CAPIK3CB
SCHEMBL13824904 0.84 ALDH1A1 (0.53) KDM4EMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL7093171 0.83 AXL (0.60) AXLKDM4ESGK1CAMKK2MAPT
SCHEMBL10561251 0.82 AKR1C2 (0.53) LMNASMN1; SMN2PIK3CDPIK3CAPIK3CB
SCHEMBL2490163 0.82 CFTR (0.48) AXLKDM4EMAPTKMT2ALMNA
SCHEMBL3713695 0.82 AXL (0.59) AXLSGK1CAMKK2MAPTMEN1
SCHEMBL4876885 0.82 AXL (0.59) AXLSGK1CAMKK2MAPTMEN1
Hydrochloric Acid SCHEMBL7093169 0.82 AXL (0.59) AXLKDM4ESGK1CAMKK2MAPT
SCHEMBL4910427 0.81 PDGFRB (0.49) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL1854140 0.81 MKNK1 (0.43) AXLNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-04 US disclosed
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-04 US disclosed
EP-0846684-A2 Process for producing 2-halo-nicotinic acid derivatives and precursors thereto REILLY INDUSTRIES, INC. (US) 1998-06-10 EP disclosed
US-5493028-A Processes for producing 2-Halo-nicotinic acid derivatives and precursors thereto REILLY INDUSTRIES, INC. (US) 1996-02-20 US disclosed
EP-0633880-A1 PROCESSES FOR PRODUCING 2-HALO-NICOTINIC ACID DERIVATIVES AND PRECURSORS THERETO REILLY INDUSTRIES, INC. (US) 1995-01-18 EP disclosed
WO-1993018005-A2 PROCESSES FOR PRODUCING 2-HALO-NICOTINIC ACID DERIVATIVES AND PRECURSORS THERETO REILLY INDUSTRIES, INC. (US) 1993-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230134932-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 AXL 3024/4885KDM4E 710/4885SGK1 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.